Distinguishing CML LSCs from HSCs using CD26

Xiaoyan Jiang1

  • 1British Columbia Cancer Agency; University of British Columbia.

Blood
|June 21, 2014
PubMed

In this issue of Blood, Herrmann et al elegantly demonstrate that CD26 is a new, specific chronic myeloid leukemia (CML) stem cell biomarker that phenotypically distinguishes leukemic stem cells (LSCs) from normal hematopoietic stem cells (HSCs), and that it is a potential therapeutic target in CML.